Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial results

NeOnc NEO100 Phase 2a Results

Analysis based on 8 articles · First reported Aug 26, 2026 · Last updated Aug 28, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The positive Phase 2a data and upcoming FDA interaction could boost investor confidence in NeOnc's pipeline, potentially supporting the stock price. However, clinical-stage risks and the need for further trials and regulatory approval temper the impact.

Biotechnology Pharmaceuticals

Neonci Technologies reported positive topline results from its NEO100-01 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The study met its primary endpoint with 48.9% six-month progression-free survival versus a prespecified 20% benchmark (p=0.0047), median overall survival of 26.09 months, and 86.7% of patients alive at six months. The company plans to request a Type B meeting with the United States — Food and Drug Administration to discuss a potential registrational pathway for NEO100. NeOnc also received UAE IND approvals for NEO100 and NEO212 in June, and insiders including CEO Amir Heshmatpour and director Thomas Chen have purchased shares. The company remains a clinical-stage biotechnology firm, and these results do not guarantee approval.

100 Neonci Technologies reported positive results
50 Neonci Technologies received IND approvals United Arab Emirates
40 Thomas Chen purchased shares Neonci Technologies
priv
NeOnc is the central entity; positive Phase 2a results and planned FDA meeting could enhance its valuation and prospects, though approval is not guaranteed.
Importance 100.0 Sentiment 70.0
govactor
The FDA is the regulatory authority that will determine the registrational pathway for NEO100; its upcoming Type B meeting is a key catalyst.
Importance 80.0 Sentiment 0.0
per
CEO Amir Heshmatpour's continued open-market purchases signal management conviction, positively reflecting on the company.
Importance 40.0 Sentiment 60.0
cnt
The UAE granted IND approvals for NEO100 and NEO212, expanding NeOnc's development reach internationally.
Importance 30.0 Sentiment 20.0
per
Director Thomas Chen's share purchases also indicate insider confidence in NeOnc's prospects.
Importance 30.0 Sentiment 50.0
exch
Nasdaq is the exchange where NTHI is listed; short interest data provides market context but is not central to the event.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.